Defense contractors are being summoned to increase the production of both missiles and defense systems, specifically Lockheed ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

Moderna Inc. MRNA shares are up during Wednesday’s premarket session following a settlement agreement with Arbutus Biopharma ...

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to two other biotechnology companies to [settle patent litigation]( ...

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

While cybersecurity demand is surging, CrowdStrike is right in the middle of it. Now, Morgan Stanley analysts just doubled ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.